21 results about "Viral therapy" patented technology

Provided are serum-resistant vaccinia extracellular enveloped viruses (EEV), methods of producing serum-resistant EEVs, and modified EEVs for systemic oncolytic viral therapy. Provided herein are methods to modify vaccinia viruses to produce serum resistant EEVs for systemic oncolytic viral therapy. Compositions containing serum resistant EEVs and methods of treating cancers and other proliferative diseases are provided.

A method for treating an immunocompromised patient including collecting from patient values for at least one variable selected from the group, inputting the values for the one or more variables to a neural network (NN) performed on one or more computers to produce a score indicative of likelihood of response or non-response to an anti-viral drug and a score indicative of likelihood of response or non-response to Virus-Specific T-Cells (VSTs) and administering an antiviral drug to a patient who has a threshold score indicative of a likelihood of a response to anti-viral therapy and administering VSTs to a patient who has a threshold score indicative of a likelihood of a response to VST therapy.

This invention relates to the field of biomedical engineering technology, and provides the application of striatin interacting protein (STRIP) inhibitors in the preparation of anti-tumor drugs, recombinant vectors of STRIP inhibitors and their application in the preparation of anti-tumor drugs, and anti-tumor pharmaceutical compositions in which STRIP inhibitors or recombinant vectors of STRIP inhibitors are used as active components. This invention aiming at STRIP inhibition can be used to prepare viral drugs for tumor treatment, in particular when it is recombined with vaccinia viruses to form recombinant vectors, which combine the advantages of STRIP inhibitors and vaccinia viruses. The invention provides a new target for viral therapy of tumor and has a broad clinical application prospect.

The present invention relates to oncolytic vaccinia viruses and recombinant viruses and methods of use thereof. In particular, the present invention provides a cloned vaccinia virus strain exhibiting enhanced anti-tumor properties and / or reduced immunogenicity, as well as a recombinant vaccinia virus derived therefrom. The present invention also provides recombinant oncolytic virus strains comprising an inactivated mutation in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses (e.g., vaccinia viruses, including recombinant vaccinia viruses) provided herein are useful as oncolytic viral therapies (e.g., oncolytic vaccinia viral therapies) for the treatment of cancer. The invention also provides pharmaceutical compositions of the virus, such as vaccinia virus, and methods and uses of the virus, such as vaccinia virus, for the treatment of cancer, as well as nucleic acids encoding the virus.

This invention relates to oncolytic vaccinia viruses, recombinant viruses thereof, and methods of use. Specifically, the invention provides vaccinia virus clone lines and recombinant vaccinia viruses derived therefrom, said vaccinia virus clone lines exhibiting enhanced antitumor properties and / or reduced immunogenicity. The invention also provides recombinant oncolytic virus lines comprising inactivating mutations in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses provided by this invention (such as vaccinia viruses, including recombinant vaccinia viruses) can be used as oncolytic virus therapies (such as oncolytic vaccinia virus therapy) for the treatment of cancer. The invention also provides pharmaceutical compositions of viruses (such as vaccinia viruses), methods and uses of viruses (such as vaccinia viruses) for the treatment of cancer, and nucleic acids encoding said viruses.

The present invention relates to compositions and methods for producing target-specific therapeutic agents with improved properties, useful in oncolytic viro therapy, gene therapy, cell therapy and immunotherapy. Specifically, the invention in embodiments thereof relates to adapter molecules, capable of directing viruses and viral vectors to specific target cells ex vivo and in vivo, to methods for their preparation and use, and to therapeutic compositions comprising them.

Provided are modified cells and cell lines containing extracellular enveloped viruses (EEV), methods of producing serum-resistant EEVs, and programmed EEVs for systemic oncolytic viral therapy. The viruses are high EEV producing viruses that contain genome modifications that alter properties and / or activities of the viruses. The cells and cell lines are modified to encode polypeptides or peptides that are displayed on their membranes, which, when virus is propagated in the cells, encases the virus so that the polypeptides and peptides from the cell membrane are displayed on the virus. The viruses, thus contain modified outer envelopes that display polypeptides and / or peptides encoded by the virus and from the cell membranes. This combination provides viruses whose properties and activities can be programmed by virtue of the cells in which they are produced and viral genome modifications. The viruses can be used for treating cancers or, because the properties of the virus, including tropisms, other diseases, disorders, and conditions involving targeted cells.

Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and / or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and / or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and / or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and / or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

The invention relates to medicine, and more particularly to hepatology, infectious diseases and oncology, and can be used for predicting hepatitis D relapse after completion of anti-viral therapy. In a liver biopsy sample from the patient, hepatitis D virus RNA is detected using a polymerase chain reaction (PCR) method. In the event of a positive PCR result for hepatitis D virus RNA in the liver biopsy sample, irrespective of a negative PCR result for hepatitis D virus RNA in the blood serum, a relapse of hepatitis D is predicted within 4-24 weeks after completion of treatment. The method provides an increase in the accuracy of predicting hepatitis D relapse after completion of anti-viral therapy by early detection of hepatitis D virus RNA in a liver biopsy sample.

The present invention provides compositions and methods for treating HPV infections, including pre-malignant and cancerous infections. Compounds that specifically bind to and inactivate the HPV E6 protein are disclosed.

The invention belongs to the technical field of biological medicines, and particularly discloses application of a lipophage receptor protein SPARTIN overexpressed adenovirus in preparation of a medicine for preventing and treating postmenopausal osteoporosis, after a lipophage receptor protein SPARTIN gene is inserted into a PLVX lentiviral vector to construct a transfection plasmid, the transfection plasmid and virus component expression plasmids PxpaX2 and PMD2G are co-transfected in an HEK 293T cell, after 48 hours, a virus supernatant is collected, and the recombinant adenovirus is obtained. The amino acid sequence of the SPARTIN protein gene is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of the SPARTIN overexpressed adenovirus. Compared with the prior art, overexpression of the lipophage receptor protein SPARTIN can supplement expression of cell lipophage receptor protein, enhance marrow lipolysis and promote bone formation, so that the purpose of treating postmenopausal osteoporosis is achieved. And finally, compared with the existing lentivirus / adenovirus therapy, the BMAs targeting property is higher, and the BMAs targeting agent is safer and more effective.

Methods are provided for treating or preventing HPV-related disease by administering to a subject a priming vaccine, and a boosting vaccine, wherein the priming and boosting vaccine each elicit an immune response against HPV. Within various embodiments either the priming vaccine or the boosting vaccine can be a recombinant oncolytic virus which expresses an immunogenic protein derived from an HPV strain which has been mutated so as to no longer cause cancer. Within other embodiments the either the priming vaccine or the boosting vaccine can be an immunogenic protein, or a molecule which expresses an immunogenic protein, wherein said immunogenic protein is derived from an HPV strain which has been mutated so as to no longer cause cancer.

The invention belongs to the technical field of biological medicine, and particularly discloses application of WAC knock-down adenovirus in preparation of medicine for preventing and treating arthritis cartilage injury, WAC protein genes are inserted into PLVX lentiviral vectors to construct transfection plasmids, the transfection plasmids and virus component expression plasmids PxpaX2 and PMD2G are co-transfected in HEK 293T cells, virus supernate is collected after 48 hours, and the WAC knock-down adenovirus is obtained. The amino acid sequence of the WAC protein gene is as shown in SEQ ID NO. 1. Compared with the prior art, after the WAC is knocked down, the generation of cartilage cell matrix metalloproteinases MMP3 and MMP13 and chemotactic factors CCL2 and CCL3 is reduced, so that the cartilage injury caused by arthritis can be prevented and treated; compared with the existing clinical therapy, the technology starts from the pathogenesis of arthritis, and the purpose of treating the arthritis cartilage injury is achieved by a method of reducing cell WAC protein expression and reducing abnormal secretion of cartilage cells; finally, compared with the existing lentivirus / adenovirus therapy, the invention has stronger targeting to cartilage cells, and is safer and more effective.

MEF2C haploinsufficiency syndrome (MCHS) is a neurodevelopmental disorder with profound impacts on the affected children and their families. Deletion or mutation of one copy of a MEF2C gene, which codes for an activity-regulated transcription factor, causes MEF2C Haploinsufficiency syndrome. Described herein are nucleic acid molecules comprising an expression cassette comprising a MEF2C isoform coding sequence and a neuronal specific promoter that is operably linked to the MEF2C isoform coding sequence. Recombinant adeno-associated virus vectors comprising the nucleic acid molecules, and self-complementary forms of adeno-associated virus vectors comprising the nucleic acid molecules. Also provided are pharmaceutical compositions for treating MEF2C haploinsufficiency syndrome, methods of treating MEF2C haploinsufficiency syndrome in a patient in need thereof, and methods of inducing transgenic expression of MEF2C in a subject.

Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and / or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and / or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.

The invention relates to the technical field of biology, and discloses an anti-flavivirus protein or polypeptide and application thereof. The antiviral protein or polypeptide provided by the invention can inhibit flavivirus replication and activity, achieves the purpose of resisting flavivirus infection or preventing flavivirus infection, and has the potential of being used as an anti-flavivirus drug. As no medicine for effectively treating flavivirus infection exists at present, the antiviral protein or polypeptide provided by the invention has a wide application prospect due to good resistance to flavivirus under the condition of lack of an appropriate antiviral therapy.

A composition for expressing a polypeptide within a target organ, the composition comprising a delivery particle, and at least a first mRNA sequence complexed with, encapsulated by, or otherwise associated with the delivery particle. The mRNA sequence comprises a coding sequence which codes for the polypeptide, at least a first untranslated region (UTR) sequence, and at least one micro-RNA (miRNA) binding site sequence, wherein the miRNA binding site sequence is located within, immediately 5′ to, or immediately 3′ to, the first UTR sequence. The composition may be used in combination with or to supplement other therapeutic approaches, including chemotherapy, oncolytic viral therapy, and cellular therapies. Methods for making and using the composition are provided, particularly in treatment of disease, such as cancer of the liver, brain, lung, breast and pancreas.

Provided herein are methods, compositions, systems and kits to identify and to make use of polyoma virus antiviral therapy. In particular, provided herein are compositions and methods to treat BK polyoma virus (BKPyV) infection comprising velpatasvir or analogs or derivatives thereof.

The present invention relates to: methods for predicting the prognosis of a virus infection in an individual; to methods for identifying an individual in need of anti-viral therapy; to related compositions; and to uses and treatment methods involving the compositions.